Ремонт ноутбука своими руками. Быстрый и гарантийный ремонт ноутбуков. Срочный ремонт ноутбуков. Ремонт компьютеров на дому. Быстрый ремонт компьютеров своими руками. Настройка и ремонт компьютеров. Java уроки для начинающих. Лучшие java уроки. Учим язык Java с нуля. Обзор смартфонов samsung. Качественный обзор смартфонов samsung galaxy. Обзор смартфона samsung galaxy s4. Фото картинки приколы. Самые новые картинки приколы. Лучшие приколы картинки. Скачать аддоны для wow. Самые новые аддоны для wow скачать. Скачать аддоны для wow быстро и без реги. Видео уроки python. Лучшие python уроки. Учим язык python с нуля. Скачать шаблоны для Joomla. Самые новые joomla шаблоны. Бесплатные шаблоны для Joomla.

Language of Website

Allakos closes $32M series a financing to develop antibody-based therapeutics

  • Wednesday, Dec 19 2012

Allakos Inc. announced today that it has completed a $32 million Series A preferred stock financing led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander , PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors.

Commented Dr. Moldt: "We believe that Allakos' innovative approach to developing antibody-based therapeutics represents a large and important therapeutic and commercial opportunity, founded upon a strong scientific rationale and supported by a respected management team with deep experience in therapeutic antibody development. We are pleased to join with these other distinguished investors in supporting their progress."

"We very much appreciate the confidence placed in our company by our Series A investors," said Christopher Bebbington , DPhil, Founder and Chief Executive Officer of Allakos. "Our therapeutic antibodies are designed to work through novel mechanisms of action, to have significant safety and efficacy advantages and to have potential in multiple, high-value markets, including large therapeutic areas as well as orphan indications. With these proceeds, we are now well positioned to advance our lead program towards meaningful near-term milestones."

SOURCE Allakos Inc.

Rate this item
(0 votes)
Login to post comments

Subscribe to our newsletter

Управление научных исследований СПбГТИ (ТУ)

Hot events

Laboratory Equipment

Rambler's Top100
//'+ 'Рейтинг@Mail.ru<\/a><\/p>');})(window,navigator,document);//]]>